Mecapegfilgrastim Prevents Neutropenia and Radiation Esophagitis
Evaluation of the efficacy and safety of Mecapegfilgrastim for the prevention of neutropenia and radiation esophagitis after hyperfractionation in patients with limited-stage small cell lung cancer
Small Cell Lung Cancer
DRUG: Mecapegfilgrastim
The incidence of neutrophil radiation esophagitis begins with hyperfractionated chemoradiotherapy., 6 weeks|Incidence of 3 and 4 degrees neutropenia within 6 weeks from the start of hyperfractionated radiotherapy, 6 weeks
Evaluation of the efficacy and safety of Mecapegfilgrastim for the prevention of neutropenia and radiation esophagitis after hyperfractionation in patients with limited-stage small cell lung cancer